Myotonic dystrophy (dystrophia myotonica, DM) is a chronic, slowly progressing, highly variable inherited multisystemic disease. It is characterized by wasting of the muscles (muscular dystrophy), posterior subcapsular iridescent cataracts, heart conduction defects, endocrine changes, and myotonia. Myotonic dystrophy can occur in patients of any age.

[edit] Classification

Two types of adult onset myotonic dystrophy exist. Type 1 (DM1), also called Steinart's disease, has a severe congenital form and a milder childhood-onset form. Also called proximal myotonic myopathy (PROMM), myotonic dystrophy type 2 (DM2) is due to a different mechanism than DM1 and generally manifests with milder signs and symptoms.

Other forms of myotonic dystrophy (DM3, DM4, and DMX) may also exist.^{[citation needed]} One recent case was proposed as a candidate for the "DM3" label,^[1] but was later characterized as a form of Paget's disease.^[2][3]

[edit] Epidemiology

Myotonic dystrophy is the most common form of muscular dystrophy affecting adults.^{[citation needed]} It is the second most common form of any skeletal muscle disease after Duchenne muscular dystrophy.^{[citation needed]}

Type 1 accounts for 98% of all myotonic dystrophy cases. Estimates of the the prevalence of type 2 muscular dystrophy may be erroneously low as the various atypical presentations of this subtype may evade diagnosis.^{[citation needed]}

[edit] Symptoms

Presentation of symptoms varies considerably by form (DM1/DM2), severity and even unusual DM2 phenotypes. DM1 patients often present with myotonia, disabling distal weakness and severe cognitive problems. DM2 patients commonly present with muscle pain, stiffness, fatigue, or the development of proximal lower extremity weakness (Day & al, 2003). The characteristic pattern of weakness is different for DM1 and DM2: In DM1, it is noted in face and jaw muscles, the drooping of the eyelids (ptosis), weakness of the neck muscles, hands and lower legs. In DM2, the weakness is more evident in proximal muscles, those closer to the trunk of the body: neck, shoulders, hip flexors and upper legs.

Symptoms classically asssociated with DM1 are generally more mild and involve the smooth muscle (including G.I. symptoms), hypersomnia (daytime sleepiness), muscle wasting, dysphagia, and respiratory insufficiency. In addition, DM1 may manifest with a cognitive abnormalities including developmental delays, learning problems, language, speech, behaviour, apathy or hypersomnia. Cognitive manifestations for DM2 include problems with executive function (eg, organization, concentration, word-finding) and hypersomnia. Conduction abnormalities are more common in DM1 than DM2, but all patients are advised to have an annual ECG. Both types are also associate with insulin resistance.

DM2 is generally milder than DM1, with generally fewer DM2 patients requiring assistive devices than DM1 patients.^{[citation needed]} In addition, the severe congenital form that affects babies in DM1 has not been found in DM2 and the early onset of symptoms is rarely noted to appear in younger patients in the medical literature.

[edit] Genetics

Myotonic dystrophy is inherited in an autosomal dominant pattern.

Myotonic dystrophy is a genetic condition which is inherited in an autosomal dominant pattern and thus will be passed along to 50% of a carrier's offspring, on average.

Myotonic dystrophy is one of several known trinucleotide repeat disorders. Certain areas of DNA have repeated sequences of two or three nucleotides.

[edit] DM1

In DM1, the affected gene is called DMPK, which codes for myotonic dystrophy protein kinase,^[4] a protein expressed predominantly in skeletal muscle.^[5] The gene is located on the long arm of chromosome 19.^[6]

In DM1, there is a repeat of the triplet cytosine-thymine-guanine (CTG) in the DMPK gene. The number of repeats varies greatly, but the average number in a healthy person is between 5 and 37. Additional trinucleotide repeats inserted during cell division can produce protein instability.^{[citation needed]} Consequently, the repeat size of an individual with DM1 will become larger usually during gametogenesis or early embryonic development. This explains the phenomenon of anticipation, as each child of an affected adult will have a larger expansion than their parent. Individuals with larger expansions have an earlier onset of the disorder and a more severe phenotype.

[edit] DM2

DM2 is caused by a defect of the ZNF9 gene on chromosome 3.^[7] The specific defect is a repeat of the cytosine-cytosine-thymine-guanosine (CCTG) tetranucleotide in the ZNF9 gene.^[7] As it involves the repeat of four nucleotides, it is not a trinucleotide repeat disorder, but rather a tetranucleotide repeat disorder.^[8]

The repeat expansion for DM2 is much larger than for DM1, ranging from 75 to over 11,000 repeats.^[7] Unlike in DM1, the size of the repeated DNA expansion in DM2 does not appear to make a difference in the age of onset or disease severity.^{[citation needed]} Anticipation appears to be less significant in DM2 and most current reviews only report mild anticipation as a feature of DM2.^{[citation needed]}

[edit] Diagnosis

The diagnosis of DM1 and DM2 can be difficult due to the large number of neuromuscular disorders, most of which are very rare. More than 40 neuromuscular disorders exist with close to 100 variants.^{[citation needed]}

As a result, patients with multiple symptoms that may be explained by a complex disorder such as DM1 or DM2 will generally be referred by their primary care physician to a neurologist for diagnosis. Depending on the presentation of symptoms, patients may be referred to a number of medical specialists including cardiologists, ophthalmologists, endocrinologists, and rheumatologists. In addition, the clinical presentation is obscured by the degree of severity or the presence of unusual phenotypes.

It is common that the clinical presentation for both DM1 and DM2 patients does not conform to the perceptions of these diseases held by many neurologists. Clinicians who are less familiar with the myotonic dystrophies in their day to day practice may expect patients with both forms to present with the more severe classic symptoms of DM1. As a result, patients may remain undiagnosed or be misdiagnosed.

Even though there is presently no cure for DM and management is currently symptom based, a precise diagnosis is still necessary because of multiple other problems that may develop over time. , cataracts). An accurate diagnosis is important to assist with appropriate medical monitoring and medical management of symptoms. In addition, genetic counseling should be made available to all patients because of the high risk of transmission. Potentially serious anesthetic risks are important to note, so the presence of this disorder should be brought to the attention of all medical providers.

[edit] Management

There is currently no cure for or treatment specific to myotonic dystrophy. Complications of the disease, including heart problems, cataracts, and other abnormalities, can be treated but not cured. However there are medical interventions and medications that may relieve some of the symptoms such as myotonia, pain, and excessive sleepiness. Some treatments have been subject to systematic review for safety and efficacy through the Cochrane Reviews for symptoms such as hypersomnia (excessive daytime sleepiness), myotonia, strength training, aerobic exercise training, and foot drop.

Recent research has provided more information on the underlying molecular pathophysiologic mechanisms involved in myotonic dystrophy and has fueled interest and research into new approaches for more specific and effective treatment. Research in areas such as high-throughput screening and antisense therapy hold hope for more effective targeted treatments for the future. Altered splicing of the muscle-specific chloride channel 1 (ClC-1) has been shown to cause the myotonic phenotype of DM1 and is reversible in mouse models using Morpholino antisense to modify splicing of ClC-1 mRNA^[9].

Progress in this area is being fueled by the sharing of research by scientists and clinicians at biannual meetings by the International Myotonic Dystrophy Consortium (IDMC). The 7th biannual meeting IDMC-7 took place in Wurtzburg, Germany September 9-12 2009.

[edit] Screening

Screening for the repeat expansions on the DMPK gene for DM1 is targeted at chromosome 19, while the ZNF9 gene for DM2 is found on chromosome 3. Genetic tests, including prenatal testing, are available for both confirmed forms. Molecular testing is considered the gold standard of diagnosis. Further forms of myotonic dystrophy (DM3, DM4, and DMX) are suspected by researchers with possible defects on chromosome 16 and chromosome 21.^{[citation needed]}

[edit] References

[edit] Further reading

• Sir Peter S. Harper, (2002). Myotonic Dystrophy: The Facts : A Book for Patients and Families (Oxford Medical Publications). Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-852586-9. 
• Peter S. Harper... [et al.] (2004). Myotonic dystrophy: present management, future therapy. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-852782-9. 
• Robert D. Wells (Editor), Tetsuo Ashizawa (Editor) (2006). Genetic Instabilities and Neurological Diseases, Second Edition, 2006. Boston: Academic Press. ISBN 0-12-369462-0.  This book has chapters on multiple disorders including both Steinert’s (DM1) and PROMM (DM2). The revised 2006 edition is the first print resource to have a full chapter on DM2: Myotonic Dystrophy Type 2: Clinical and Genetic Aspects by Krahe, Bachinski, and Udd This book is intended to be a reference for medical professionals such as neurologists, neuroscientists, biochemists, geneticists, molecular biologists & human geneticists.

[edit] External links

Overview of condition at NLM Genetics Home Reference

• Searchable database at Dutch Neuromuscular Research
• 140th ENMC International Workshop 2006 Myotonic Dystrophy DM2/PROMM and other Myotonic dystrophies]
• Information from the Myotonic Dystrophy Foundation
• Information from the International Myotonic Dystrophy Organization
• MDSG Information
• Information from the Neuromuscular Disease Center
• DM Toolbox Research tools for Myotonic Dystrophy from the Marigold Foundation